摘要
目的评价马盐酸法舒地尔注射液联合来酸桂哌齐特注射液治疗动脉瘤性蛛网膜下腔出血术后脑血管痉挛的效果,为临床治疗提供依据。方法选取南充市中心医院神经外科2016年1月~2017年3月共收治的动脉瘤性蛛网膜下腔出血术后发生脑血管痉挛患者72例,采用随机数字表法分为对照组和观察组各36例。对照组给予盐酸法舒地尔注射液治疗,观察组给予盐酸法舒地尔注射液联合马来酸桂哌齐特注射液治疗,比较两组治疗前后白细胞介素6(IL-6)水平、CT评分、格拉斯哥预后(GOS)评分、临床疗效、不良反应情况。结果两组IL-6水平在治疗后均明显降低,观察组下降更明显,差异有统计学意义(P<0.01);对照组与观察组的CT评分与GOS评分均呈负相关(r=-0.635、0.741,P<0.05);总有效率上观察组(91.67%)高于对照组(72.22%),差异有统计学意义(P<0.05);两组不良反应发生率相当,差异无统计学意义(P>0.05)。结论盐酸法舒地尔联合马来酸桂哌齐特能有效防治动脉瘤性蛛网膜下腔出血术后脑血管痉挛,抑制炎症因子,不良反应少,安全性好。
Objective To evaluate the effect of Fasudil Hydrochloride combined with Cinepazide Maleate in the treatment of cerebral vasospasm(CVS)after aneurismal subarachnoid hemorrhage(aSAH),and to provide evidences for clinical treatment.Methods Seventy-two patients with CVS after aSAH were selected in the Nanchong Central Hospital from January 2016 to March 2017,and divided into control group and observation group by random number table method,with 36 cases in each group.The control group was treated with Fasudil Hydrochloride,and the observation group was treated with Cinepazide Maleate combined with Fasudil Hydrochloride,the levels of IL-6 before and after treatment,CT score,GOS Score,clinical efficacy,adverse events were compared between two groups.Results The levels of IL-6 were decreased significantly after treatment in two groups,and the observation group was significantly lower than the control group,with statistical significance(P<0.01).The CT score was negatively correlated with GOS score in the control group and observation group(r=-0.635,-0.741,P<0.05).The total effective rate of observation group(91.67%)was higher than that of control group(72.22%),with statistical significance(P<0.05).The incidence of adverse events was similar between two groups,with no statistical significance(P>0.05).Conclusion Fasudil Hydrochloride combined with Cinepazide Maleate has significant therapeutic efficacy on CVS after aSAH,and can effectively inhibit inflammatory factors and reduce adverse events with good safety.
作者
罗孝全
唐辉
李承科
陈兵
邵川
LUO Xiaoquan;TANG Hui;LI Chengke;CHEN Bing;SHAO Chuan(Department of Neurosurgery,Nanchong Central Hospital,Sichuan Province,Nanchong 637000,China)
出处
《中国医药导报》
CAS
2018年第8期76-79,共4页
China Medical Herald
